ADAM17 mediates MMP9 expression in lung epithelial cells.

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• Matrix metalloproteinase 9 (MMP9) plays a role in various physiological and pathological processes.
• Tumor necrosis factor-alpha (TNF-α) and nuclear factor-kappa B (NF-κB) signaling pathways are implicated in inflammatory responses and gene expression.

Purpose of the Study:

• To elucidate the role of TNF-α/NF-κB signaling in lipopolysaccharide (LPS)-induced MMP9 expression in A549 lung epithelial cells.
• To investigate the impact of targeting the disintegrin and metalloproteinase 17 (ADAM17) gene using lentivirus-mediated RNA interference (RNAi) on LPS-induced MMP9 expression.

Main Methods:

• Dose- and time-dependent analysis of LPS-induced MMP9 expression in A549 cells.
• Inhibition studies using pyrrolidine dithiocarbamate (PDTC) and a TNFR1 blocking peptide (TNFR1BP).
• Assessment of TNF-α production, IκBα phosphorylation, and p65 protein phosphorylation following LPS stimulation and ADAM17 RNAi.

Main Results:

• LPS significantly upregulated MMP9 expression in a dose- and time-dependent manner.
• PDTC and TNFR1BP inhibited LPS-induced MMP9 expression, TNF-α production, and NF-κB pathway activation.
• Lentivirus-mediated ADAM17 RNAi suppressed LPS-induced MMP9 expression by inhibiting TNF-α/NF-κB signaling.

Conclusions:

• LPS induces MMP9 expression in A549 cells through the TNF-α/NF-κB signaling pathway.
• Inhibition of ADAM17 expression via RNAi effectively downregulates LPS-induced MMP9 expression.
• Targeting ADAM17 presents a potential therapeutic strategy for conditions involving aberrant MMP9 activity in lung epithelial cells.